• Onset: NOT acute. There is no first-dose effect. Bacopa is a chronic-dosing compound; the cognitive shift is structural (BDNF, dendritic remodeling) and emerges over weeks.
• Week 1-4: typically nothing felt. Some users report mild GI tone changes (the saponins are gut-active), occasional drowsiness, mildly easier sleep.
• Week 4-8: the "trough" period — some users report mild fog/dullness ("Bacopa fog") before the consolidation benefit arrives; others feel calmer, less reactive.
• Week 8-12: the consolidation effect emerges. Subjectively this is easier word retrieval, sharper memory of recent events, decreased forgetting of names/details, and a calmer baseline under cognitive pressure. It is not a felt nootropic high — there is no peak. It's a shift in baseline.
• Week 12+: sustained effect; benefit plateaus by ~16 weeks.
• Sedation profile: ~5-15% of users report consistent mild sedation, especially at PM doses or higher (450-600 mg). This is dose- and timing-dependent — moving the dose to AM with breakfast resolves it for most.
• Mood smoothing: the 5-HT1A action produces a subtle anxiolytic/mood-stabilizing effect for many users; for a subset, this presents as flatness or reduced motivation drive. Important counter to the consolidation benefit — more notably for high-drive individuals.

• Tolerance buildup: minimal-to-none documented. The mechanism (BDNF, dendritic remodeling, slow cholinergic upregulation) is structural rather than receptor-occupancy-driven, so receptor downregulation isn't the dominant kinetic. Long-term users report stable benefit out to ≥12 months.
• Recommended cycle: not strictly required. Some traditional Ayurvedic protocols cycle 3 months on / 1 month off; modern clinical use often runs continuous 6-12 months. For Dylan: continuous use is fine if the 12-week trial is positive; consider a 4-week washout once a year for re-baseline assessment.
• Reset protocol if needed: 4-week washout fully clears bacosides (half-life is short despite the long onset to clinical effect — the kinetics decouple from the dynamics because of the structural mechanism). Cognitive benefit will partially fade within 2-4 weeks of cessation; full return-to-baseline by 6-8 weeks.

Synergistic with

• lions-mane: ✅ Different neurotrophic pathway (NGF vs BDNF) — combination is mechanistically clean and frequently used together in cognitive longevity stacks. Both slow-onset; expect 8-12 week timelines.
• citicoline: ✅ Already in Dylan's V4 (500 mg/day). Citicoline provides choline + cytidine substrate; Bacopa enhances ACh utilization downstream. Synergy is plausible mechanistically and reported anecdotally.
• alcar: ✅ Bacopa's ChAT upregulation + ALCAR's acetyl group donation = parallel cholinergic substrate stack. Both AM-dosed for Dylan. Stack-safe.
• DHA / omega-3 (V4 already): ✅ Membrane substrate + neurotrophic synergy; classic memory stack.
• Phosphatidylserine (V4 already): ✅ Membrane support + Bacopa's neurotrophic action; stack-safe.
• Curcumin / curcumin phytosome (V4 already): ✅ Antioxidant + anti-inflammatory parallel to Bacopa's HSP70/SOD induction; commonly stacked for neuroprotection.
• L-theanine (V4 already): ✅ Both anxiolytic, different mechanisms (theanine via GABA/glutamate balance, Bacopa via 5-HT1A); combine fine, watch for additive sedation.
• Ashwagandha: ✅ HPA-axis adaptogen; commonly co-formulated with Bacopa in Ayurvedic stacks. Watch for additive sedation/mood-flattening in high-drive individuals.

Avoid stacking with

• Pharmaceutical AChE inhibitors (donepezil, galantamine, rivastigmine) — additive cholinergic risk (nausea, bradycardia, depression, "wet" feeling). Not relevant for Dylan but flag for any older user.
• High-dose huperzine A (>200 mcg) — same logic as above; mild AChE addition can stack uncomfortably.
• Beta-blockers — Bacopa's mild bradycardia/hypotension can stack with beta-blockers in sensitive users. Watch resting HR.
• Sedating compounds at PM (high-dose magnesium glycinate at bedtime, glycine, melatonin) — additive sedation if Bacopa is dosed evening. Solution: Bacopa AM only.

Neutral / safe co-administration

• All other V4 stack items: NAC, magnesium glycinate, magnesium L-threonate (Magtein), rhodiola, glycine, D3+K2, beta-alanine, vitamin C, creatine.
• All planned V5 additions: modafinil, bromantane, Adamax/Semax, ALCAR, apigenin, taurine, astaxanthin, L-tryptophan.

• Thyroid hormone (levothyroxine, T3, NDT): Bacopa increases T4 → T3 conversion modestly; could subclinically elevate free-T3 in supplemented hyperthyroid patients or alter dose requirements in hypothyroid patients on replacement. Monitor TSH/free-T3/free-T4 if combining long-term.
• CYP3A4: Bacopa is a modest CYP3A4 inhibitor in vitro and in some rodent studies. Clinical magnitude in humans appears small at standard doses (300 mg/day) but flagged for narrow-therapeutic-index CYP3A4 substrates (cyclosporine, tacrolimus, certain statins, midazolam, certain calcium channel blockers). Not relevant for Dylan's current stack.
• CYP2C19, CYP1A2, CYP2D6: weaker / inconsistent inhibition signals; generally not clinically meaningful at supplement doses.
• Phenytoin: Bacopa increased phenytoin brain concentrations in animal models — caution for epilepsy patients on phenytoin maintenance.
• Calcium channel blockers + amlodipine: theoretical additive hypotension; clinical significance low at standard doses.
• Anticoagulants: weak / theoretical; no replicated bleeding signal but worth noting for patients on warfarin.
• Sedatives / benzodiazepines / alcohol: additive sedation possible in the 5-15% sedation-responder subset.
• AChE inhibitors: additive cholinergic effects (see Avoid stacking).
• Contraceptives: no documented interaction.

Bacopa pharmacogenomics is thinly studied compared to ALCAR or modafinil. Main signals:

• APOE genotype — some animal and small clinical evidence that APOE4 carriers may benefit more from Bacopa's neuroprotective + cholinergic effects, since APOE4 is associated with reduced cholinergic tone in aging. Inconclusive in young adults.
• BDNF Val66Met (rs6265) — Met allele carriers have impaired activity-dependent BDNF secretion. Theoretically, BDNF-upregulating compounds like Bacopa could be especially beneficial in Met carriers, though clinical confirmation is limited.
• CYP3A4 / CYP2C19 polymorphism — modulates Bacopa's CYP-inhibition effect on co-administered drugs more than Bacopa's own kinetics.
• Action for Dylan: when 23andMe results land (~June 5-15, 2026), check APOE + BDNF Val66Met. If APOE4-positive or BDNF Met carrier, the case for Bacopa strengthens; if neither, the verdict stands.

Recommendation for Dylan: Nootropics Depot Synapsa caps for the 12-week trial. Using the exact extract from the Stough RCTs maximizes the chance of seeing the trial-grade effect — supplements that just say "50% bacosides" are not equivalent to a specific clinically-validated extract like CDRI-08/Synapsa. Worth the $5/month premium over generic.

Total cost estimate: $8-15/month for 300 mg/day standardized. Negligible relative to V4/V5 budget.

Form note: Bacopa is sold as standardized extract (CDRI-08 / Synapsa, BacoMind, BaCognize — each has a slightly different bacoside profile but all clinically validated) or whole-leaf powder (less reliable because bacoside content varies seasonally). Always pick a standardized extract — whole-leaf is for tea-enthusiast use, not nootropic dosing.

Baseline (before starting)

• Subjective cognitive baseline: structured 1-10 ratings on memory, word retrieval, sparring sharpness, mood, sleep onset. Critical for a slow-onset compound where you need to compare week 12 to week 0.
• TSH, free T3, free T4 — Bacopa may shift T4→T3 conversion.
• ALT, AST — baseline liver function (rare hepatotoxicity signal).
• Resting HR + BP — Bacopa can mildly lower both; relevant for athletes with already-low resting HR.
• CBC, hs-CRP, fasting glucose — general baseline (already covered in Dylan's June panel).

During use

• Subjective cognitive tracking at weeks 0, 4, 8, 12, 16. Memory recall, word-finding, learning-new-material ease, sparring decision-making sharpness, business-task retention, mood, sleep, drive.
• Resting HR weekly for first 4 weeks (Dylan's Colmi R06 ring covers this).
• Sleep onset latency — watch for excessive drowsiness from a single AM dose carrying into PM training.

Post-cycle (if discontinuing)

• TSH/free T3 at 4-week washout — confirm thyroid markers return to baseline if they shifted.
• ALT/AST if any elevation during use — confirm normalization.
• Subjective cognitive baseline at 8-week washout — gauge how much benefit was Bacopa-dependent.